Molecular Cancer Therapeutics Landon Prizes for Basic and Translational Cancer Research Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munshi, A.
Right arrow Articles by Meyn, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munshi, A.
Right arrow Articles by Meyn, R. E.
Mol Cancer Ther. 2006;5:1967-1974
© 2006 American Association for Cancer Research

Research Articles: Therapeutics

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of {gamma}-H2AX foci

Anupama Munshi1, Toshimitsu Tanaka1, Marvette L. Hobbs1, Susan L. Tucker2, Victoria M. Richon3 and Raymond E. Meyn1

1 Departments of Experimental Radiation Oncology and 2 Biomathematics and Applied Statistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and 3 Merck & Co., Inc., Boston, Massachusetts

Requests for reprints: Anupama Munshi, Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Box 066, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-4864; Fax: 713-794-5369. E-mail: amunshi{at}mdanderson.org


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Vorinostat (suberoylanilide hydroxamic acid) is the prototype of a family of hybrid polar compounds that can induce growth arrest in transformed cells and shows promise for the treatment of cancer. Vorinostat specifically binds to and inhibits the activity of histone deacetylases resulting in acetylation of nucleosomal histones and an activation of gene transcription. Because histone deacetylases modulate chromatin structure and gene expression, both of which can influence radioresponse, this study was designed to examine the capacity of Vorinostat to influence radiation response in human tumor cells and investigate the mechanism underlying these interactions. Vorinostat induced hyperacetylation of histone H4 in a dose-dependent manner. We tested its ability to radiosensitize three human tumor cell lines (A375, MeWo, and A549) using clonogenic cell survival assays. Clonogenic cell survival assay showed that Vorinostat significantly radiosensitized all three tumor cell lines, substantially reducing the surviving fraction at 2 Gy. We examined potential mechanisms that may contribute to the enhanced radiation response induced by Vorinostat. Vorinostat and radiation alone did not induce apoptosis in the melanoma cell line. However, enhanced apoptosis was observed when cells were exposed to both Vorinostat and radiation, suggesting that Vorinostat renders tumor cells more susceptible to radiation-induced apoptosis. Results from DNA damage repair analysis in cultured A375 cells showed that Vorinostat had a strong inhibitory effect on the nonhomologous end joining pathway after radiation. A detailed examination of the involvement of the DNA repair pathway following Vorinostat treatment showed that Vorinostat reduced the expression of the repair-related genes Ku70, Ku80, and Rad50 in A375 cells as detected by Western blot analysis. We also examined {gamma}-H2AX phosphorylation as a predictive marker of radiotherapy response to Vorinostat and observed that the combination of Vorinostat and radiation caused a prolongation of expression of DNA repair proteins such as {gamma}-H2AX. Overall, we conclude that Vorinostat enhances tumor radioresponse by multiple mechanisms that may involve antiproliferative growth inhibition and effects on DNA repair after exposure to radiation. [Mol Cancer Ther 2006;5(8):1967–74]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The regulation of acetylation of lysine residues on the NH2-terminal tails of histones is a major mechanism controlling cellular differentiation and the biological behavior of cancer cells. Histone acetylation modulates nucleosome and chromatin structure and regulates transcription factor accessibility and function and, in general, chromatin composed of nucleosomes with hypoacetylated histones is transcriptionally silent (1, 2). The turnover of histone acetylation is regulated by the opposing enzymatic activities of histone acetyltransferases and histone deacetylases (HDAC; ref. 3). Importantly, dysregulated HDAC activity has been found in certain human cancers and such tumor cells are unable to undergo normal cellular differentiation possibly contributing to their neoplastic transformation (3, 4). Thus, targeting HDACs with small-molecule inhibitors is currently being tested as a therapeutic strategy for treating human malignancies.

Several compounds, such as butyrates, the anticonvulsant valproic acid, and the antifungal agent trichostatin A, have been shown to act as HDAC inhibitors, but their clinical effectiveness has been limited by low potency, high toxicity, or poor stability (5–7). A class of novel synthetic hybrid polar compounds with potent inhibitory effect on HDAC activity has been described. The prototype of this class of compounds, hydroxamic acid–based suberoylanilide hydroxamic acid (also known as Vorinostat), causes accumulation of acetylated histones in cultured cells, induces differentiation and/or apoptosis of transformed cells in culture, and inhibits the growth of tumors in animals (8–10). The inhibition of HDACs by Vorinostat occurs through a direct interaction with the catalytic site of the enzyme, as shown by X-ray crystallography studies, and leads to the accumulation of acetylated histones H2a, H2b, H3, and H4 (11). The result of HDAC inhibition is believed not to have a generalized effect on the genome but rather only affects the transcription of a small subset of genes. Vorinostat has been shown to selectively induce the expression of a specific set of genes (12).

The primary effect of HDAC inhibition is one of cytostasis in most solid tumor cell lines, suggesting that HDAC inhibitors will have only limited success as single modalities for most solid tumors. Because HDAC modulates chromatin structure and gene expression, variables considered to influence radioresponse, we investigated the effects of Vorinostat on the radiosensitivity of three human tumor cell lines growing in vitro: A375 and MeWo (human melanoma) and A549 (non–small-cell lung cancer). Exposure of these cells to Vorinostat, 24 hours before irradiation, resulted in a significant increase in radiosensitivity. Using A375 cells as a model system, we have shown that Vorinostat has the ability to down-regulate several key proteins involved in the nonhomologous end joining pathway, which is critical for repairing radiation-induced DNA double-strand breaks. In addition, treatment with Vorinostat prolonged the appearance of repair foci identified by phosphorylated H2AX ({gamma}-H2AX). Based on these findings, we believe that the radiosensitizing effect of Vorinostat is due to its ability to inhibit the repair of radiation-induced lesions in DNA.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell Lines
The human melanoma cell lines A375 and MeWo were obtained from the American Type Culture Collection (Manassas, VA) and routinely maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 10,000 units/mL of penicillin-streptomycin, and 2 mmol/L L-glutamine. The human non–small-cell lung cancer cell line A549 was obtained from American Type Culture Collection and routinely maintained in F-12/Ham medium supplemented with 10% fetal bovine serum, 10,000 units/mL of penicillin-streptomycin, and 2 mmol/L L-glutamine.

Chemicals
Vorinostat (suberoylanilide hydroxamic acid) was obtained from ATON Pharma (Tarrytown, NY). A 10 mmol/L stock was prepared in DMSO and stored at –70°C in aliquots until further use.

Cell Cycle Analysis
Cell cycle arrest was assessed by propidium iodide staining and fluorescence-activated cell sorting analysis. Cells were harvested after 24 hours of treatment with Vorinostat, pelleted by centrifugation, and resuspended in PBS containing 50 µg/mL propidium iodide, 0.1% Triton X-100, and 0.1% sodium citrate. Samples were stored at 4°C for 16 hours and vortexed before fluorescence-activated cell sorting analysis (BD PharMingen FACScan, FL-3 channel; BD PharMingen, San Diego, CA). The cell cycle calculations were done with the MultiCycle Program from Phoenix Flow Systems (San Diego, CA).

DNA Fragmentation
Apoptosis-specific DNA fragmentation was measured by a modification of a published procedure (13). The assay is based on the solubility of low molecular weight DNA in solutions of low salt concentration. Briefly, cells labeled by [14C]TdR incorporation for one cycle were treated with Vorinostat for 24 hours. The cells were irradiated and incubated for an additional 4 hours to allow apoptosis. Cells were harvested after treatment, washed with PBS, and then lysed with 0.5 mL of lysis buffer [10 mmol/L Tris, 1 mmol/L EDTA, 0.2% Triton X-100 (pH 7.5)] on ice for 20 minutes. The chromatin was pelleted by centrifugation at 14,000 x g for 10 minutes. The supernatant (fragmented DNA) was removed and the chromatin pellet was solubilized in 1 mL of Soluene (Packard, Meriden, CT). Radioactivity was determined with a liquid scintillation counter (Packard Instruments, Downers Grove, IL). DNA fragmentation was expressed as the percentage of radioactivity found in the supernatant fraction compared with the total radioactivity (pellet plus supernatant).

Clonogenic Survival
The effectiveness of the combination of Vorinostat and ionizing radiation was assessed by clonogenic assays. Briefly, the human tumor cells were treated with the vehicle control (DMSO) or Vorinostat at the indicated concentration for 24 hours and then irradiated with a high dose-rate 137Cs unit (4.5 Gy/min) at room temperature. Following treatment, cells were trypsinized and counted. Known numbers were then replated in 100-mm tissue culture dishes and returned to the incubator to allow macroscopic colony development. Colonies were counted after ~14 days and the percent plating efficiency and fraction surviving a given treatment were calculated based on the survival of nonirradiated cells treated with the vehicle or Vorinostat.

Western Blot Analysis
Cells were harvested after treatment with various doses of Vorinostat for 24 hours at 37°C, rinsed in ice-cold PBS, and lysed in lysis buffer containing 50 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L EDTA, 2 µg/mL leupeptin, 2 µg/mL aprotinin, 5 µg/mL benzamidine, 0.5 mmol/L phenylmethylsulfonylfluoride, and 1% NP40. The lysates were centrifuged at 14,000 rpm to remove any cellular debris. Protein concentrations of the lysates were determined by the Bio-Rad Dc protein assay system (Hercules, CA). Equal amounts of protein were separated by 12% SDS-PAGE, transferred to Immobilon (Millipore, Bedford, MA), and blocked with 5% nonfat dry milk in TBS-Tween 20 (0.05%, v/v) for 1 hour at room temperature. The membrane was incubated with primary antibody overnight. Antibodies to histone H4 and acetylated histone H4 were obtained from Upstate Biotechnology (Lake Placid, NY); Ku70, Rad50, and Bax were from Santa Cruz Biotechnology (Santa Cruz, CA); Ku86 was from Sigma Chemicals (St. Louis, MO); p21 was from Oncogene Sciences (Uniondale, New York, NY); and actin was from Chemicon (Temecula, CA). After washing, the membrane was incubated with the appropriate horseradish peroxidase secondary antibody (diluted 1:2,000; Amersham Pharmacia Biotech, Arlington Heights, IL) for 1 hour. Following several washes, the blots were developed by enhanced chemiluminescence (Amersham).

Immunofluorescent Staining for {gamma}-H2AX
Cells were grown and treated with 2.5 µmol/L Vorinostat for 24 hours on coverslips placed in 35-mm dishes. At specified times, medium was aspirated and cells were fixed in 1% paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde was aspirated and the cells were fixed in 70% ethanol for 10 minutes at room temperature, followed by treatment with 0.1% NP40 in PBS for 20 minutes. Cells were then washed in PBS twice and then blocked with 5% bovine serum albumin in PBS for 30 minutes, following which anti-{gamma}-H2AX antibody (Trevigen, Gaithersburg, MD) was added at a dilution of 1:300 in 5% bovine serum albumin in PBS and incubated overnight at 4°C with gentle shaking. Cells were then washed thrice in PBS before incubating in the dark with a FITC-labeled secondary antibody at a dilution of 1:300 in 5% bovine serum albumin in PBS for 30 minutes. The secondary antibody solution was then aspirated and the cells were washed four times in PBS. Cells then were incubated in the dark with 4',6-diamidino-2-phenylindole (1 µg/mL) in PBS for 5 minutes and coverslips were mounted with an antifade solution (Molecular Probes, Eugene, OR). Slides were then examined on a Leica fluorescent microscope. Images were captured by a charge-coupled device camera and imported into Advanced Spot Image analysis software package for storage purposes. For each treatment condition, {gamma}-H2AX foci were counted by eye in at least 50 cells from the stored images.

Statistical Analysis
Most analyses were done using t test (two-sample assuming unequal variances) and described as mean ± SE (Sigma Plot 5.02v, Richmond, CA). At each time point examined, ANOVA was used to test whether the average number of {gamma}-H2AX foci per cell after combined Vorinostat/radiation treatment was greater than expected from the sum of the foci produced by each agent alone.4 A difference was regarded as significant if P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Vorinostat Treatment Leads to Acetylation of Histones
We determined the degree of histone acetylation in A375 cells after culture with Vorinostat. Western blot analysis showed that before incubation with Vorinostat, the levels of acetylated histone H4 were low and did not increase remarkably with 1 µmol/L Vorinostat for 24 hours. However, incubation with 2.5 µmol/L Vorinostat for 24 hours resulted in the maximal accumulation of acetylated histone H4 in the A375 cells (Fig. 1 ). The levels of accumulated acetylated histones remained unchanged with a further increase in Vorinostat. Nonacetylated histone H4 was included as a control (Fig. 1). The effect of Vorinostat on p21 and Bax protein levels was also determined by Western blot analysis. The expression levels of p21 and the proapoptotic protein Bax have previously been shown to increase significantly with Vorinostat treatment (14, 15). There was a dose-dependent accumulation of p21 as well as Bax following exposure to Vorinostat for 24 hours (Fig. 1).


Figure 1
View larger version (9K):
[in this window]
[in a new window]
  		Figure 1. Vorinostat leads to accumulation of acetylated histone H4, p21, and Bax. A375 melanoma cells were treated with indicated concentrations of Vorinostat for 24 h. Protein was extracted and analyzed by Western blot. Nonacetylated histone H4 was used as a control for acetylated histone H4. Actin was used as a loading control for p21 and Bax. Representative of at least two independent experiments.

 
Vorinostat Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells
To assess the effects of Vorinostat on cell cycle arrest, cells were treated with 2.5 µmol/L Vorinostat for 24 hours. Cell cycle distributions of irradiated cells were compared with controls and, as shown in Fig. 2A , Vorinostat alone caused an increase in cells primarily in the G1 (67.5%) phase; 12.1% of cells were in the G2 phase and 20.4% in the S phase. A significant G2-M-phase block was observed in response to radiation; 48% versus 25% in the untreated controls. After combined drug and radiation treatment, cells accumulated in the G2 phase (42.8%) with a concomitant reduction in the G1-phase cells (31.6%; Fig. 2A).


Figure 2
View larger version (20K):
[in this window]
[in a new window]
  		Figure 2. Vorinostat alters the cell cycle profile in human A375 melanoma cells and induces apoptosis. A, cell cycle analysis of A375 cells. Cells were pretreated with 2.5 µmol/L Vorinostat for 24 h, following which they were irradiated at 5 Gy and harvested for cell cycle analysis 4 h later. Control cells were exposed to vehicle (DMSO) and subjected to the same protocol. B, apoptosis induction in the A375 cells as determined by DNA fragmentation assay. Cells were exposed to increasing concentrations of Vorinostat for 24 h, following which they were irradiated at 5 Gy and harvested for DNA fragmentation 4 h later. Columns, average of two independent experiments; bars, SE.

 
The A375 melanoma cell line was also tested for its susceptibility to Vorinostat-induced apoptosis with a DNA fragmentation assay. The DNA fragmentation assay showed that there was a dose-dependent induction of apoptosis with Vorinostat in the A375 cells (Fig. 2B). Apoptosis increased from 0.1% in the control cells to 4.5%, 8.5%, and 10.8% following a 24-hour incubation with 2.5, 5, and 10 µmol/L dose of Vorinostat respectively. A 5-Gy dose of ionizing radiation alone did not induce apoptosis but, when given at the end of the 24-hour treatment with 2.5 µmol/L Vorinostat, apoptosis was significantly enhanced in the A375 cells when compared with 2.5 µmol/L Vorinostat alone (P = 0.01). Similarly, ionizing radiation in combination with 5 and 10 µmol/L Vorinostat significantly enhanced apoptosis when compared with Vorinostat alone at the same dose (P = 0.01).

Treatment with Vorinostat Enhances Radiosensitivity of Human Tumor Cells in an In vitro Clonogenic Survival Assay
We determined the survival of human tumor cells exposed to combinations of Vorinostat and ionizing radiation using clonogenic assays. MeWo, A375, and A549 cells were pretreated with 2.5 µmol/L Vorinostat for 24 hours, following which the cells were irradiated and plated for clonogenic cell survival. Figure 3 shows that Vorinostat suppressed the clonogenic survival of all three tumor cell lines, MeWo, A375, and A549. Survival at 2 Gy was reduced from 44 ± 0.6% in the control cells to 26 ± 0.7% in the Vorinostat-treated A375 cells (P = 0.0047; Fig. 3A). Similar results were obtained on exposure of MeWo cells to Vorinostat, with surviving fraction at 2 Gy being reduced from 52 ± 0.6% in the control MeWo cells to 22.6 ± 0.5% in Vorinostat-treated MeWo cells (P = 0.001; Fig. 3B). In the A549 cells, surviving fraction at 2 Gy decreased from 61.25 ± 0.61% in control cells to 22.6 ± 1.24% with Vorinostat. The plating efficiencies for the cell lines were reduced by 2.5 µmol/L Vorinostat alone from 54% to 28% for A375, 46% to 23% for MeWo, and 58% to 35.5% for A549. Dose enhancement factors were calculated at 10% cell survival by dividing the dose of radiation from the radiation-only survival curve with the corresponding dose from the Vorinostat plus radiation curve. Dose enhancement factors were 1.34 for the MeWo cells, 1.4 for A375, and 1.7 for A549.


Figure 3
View larger version (9K):
[in this window]
[in a new window]
  		Figure 3. Treatment with Vorinostat sensitizes human tumor cells to ionizing radiation. Radiosensitization by Vorinostat was assessed on the basis of clonogenic cell survival assays. A375 (A), MeWo (B) and A549 (C) cells were pretreated with 2.5 µmol/L Vorinostat for 24 h, following which the drug was washed off and cells were irradiated with various doses of radiation and plated for cell survival. Points, average of three independent experiments each plated in triplicate; bars, SE.

 
Modulation of DNA-Repair Gene Expression by Vorinostat
As an initial investigation into the mechanism responsible for Vorinostat-mediated radiosensitization, we examined the effect of Vorinostat treatment on the expression of proteins known to be involved in the repair of radiation-induced double-strand breaks. It has been reported that suppressed levels of these proteins enhance the radiosensitivity of human tumor cells. Western blot analysis for Ku70, Ku86, and Rad50 was done on whole-cell extracts harvested from Vorinostat-treated cells (Fig. 4 ). The levels of all these proteins decreased following Vorinostat treatment in the A375 melanoma cell line. There was a dose-dependent decrease in the levels of Ku70, Ku86, and Rad50 proteins following treatment with Vorinostat in both irradiated and nonirradiated cells. Decreases in Ku70 and Ku86 levels were evident at the 2.5 µmol/L dose of Vorinostat, with maximum decrease observed at the 10 µmol/L concentration. Ionizing radiation alone did not change Ku70, Ku86, or Rad50 protein levels at 4 hours postirradiation compared with untreated controls (Fig. 4).


Figure 4
View larger version (6K):
[in this window]
[in a new window]
  		Figure 4. Involvement of DNA repair proteins in Vorinostat-mediated radiosensitization process. A375 cells were exposed to the designated concentration of Vorinostat for 24 h, following which they were irradiated with 5 Gy and incubated for an additional 4 h. At the end of the treatment, cells were collected for immunoblot analysis for Ku70, Ku86, and Rad50. Actin was used as a loading control.

 
Vorinostat Prolongs the Expression of {gamma}-H2AX Foci
To test the hypothesis that Vorinostat impairs the repair of damaged DNA, {gamma}-H2AX foci were assessed as indicators of DNA damage. As shown by the micrographs in Fig. 5A , {gamma}-H2AX foci could be clearly distinguished after irradiation (2 Gy) of A375 cells. The average number of {gamma}-H2AX foci per cell was counted in the micrographs and the results are presented in Fig. 5B. Treatment with Vorinostat alone had a slight effect on {gamma}-H2AX foci that was not statistically significant compared with untreated controls. We also tested the significance of the increase in foci per cell seen for the Vorinostat plus radiation time points compared with the foci produced by radiation alone and those produced by Vorinostat alone. These tests indicated that the foci per cell for the Vorinostat plus radiation were significantly increased at 30 minutes (P = 0.02), 1 hour (P = 0.005), and 2 hours (P = 0.008) compared with the foci produced by Vorinostat alone. A similar increase in foci per cell for Vorinostat and radiation was seen when compared with radiation alone at 30 minutes (P = 0.06), 1 hour (P = 0.008), and 2 hours (P = 1.006). We also tested the significance of the increase in foci per cell seen for the Vorinostat plus radiation time points compared with the sum of foci produced radiation and Vorinostat when used as single agents. These tests indicated that the foci per cell Vorinostat plus radiation were significantly increased at 30 minutes (P < 0.001), 1 hour (P < 0.001), 2 hours (P < 0.001), and 24 hours (P < 0.03). This prolongation of {gamma}-H2AX foci levels following the combination is consistent with an inhibition of the repair of DNA damage by Vorinostat.


Figure 5
View larger version (24K):
[in this window]
[in a new window]
  		Figure 5. Influence of Vorinostat on radiation-induced {gamma}-H2AX foci. A375 cells growing on slides in 35-mm dishes were pretreated with 2.5 µmol/L Vorinostat for 24 h, irradiated (2 Gy), and fixed at the specified times for immunocytochemical analysis of nuclear {gamma}-H2AX foci. A, micrographs obtained from cells exposed to Vorinostat. B, quantitative analysis of foci present in the cells following various treatments. Columns, mean of three independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have previously reported on the ability of HDAC inhibitors: sodium butyrate, phenylbutyrate, tributyrin, and trichostatin A (TSA) to restore radiosensitivity to human melanoma cells (16). Although sodium butyrate and phenylbutyrate synergistically interact with radiation, their short half-life in vivo and the requirement of high concentrations (millimolar) to achieve inhibition of HDAC activity make them unsuitable for clinical use (6). Similarly, use of trichostatin A is limited due to the excessive cytotoxicity associated with its mode of action. For that reason, HDAC inhibitors with longer half-life, lower toxicity, and greater stability have been developed, including Vorinostat (suberoylanilide hydroxamic acid), which is the prototype for a family of hybrid polar compounds that induce growth arrest in transformed cells (11, 17). Vorinostat induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of HDACs (8–11). In addition, it has shown great promise in clinical trials (18). In the present study, we have shown that Vorinostat sensitizes a panel of human tumor cell lines of various origins to ionizing radiation. Our results are consistent with and confirm a recent report showing the ability of Vorinostat to synergistically enhance radioresponse of human tumor cells (19). Chinnaiyan et al. (19) have shown in their study the ability of Vorinostat to abrogate key DNA damage repair processes and attenuate prosurvival signals, thereby conferring radiosensitivity to human prostate cancer and glioma cells (19).

However, in spite of a growing interest in combining HDAC inhibitors with radiation as a clinical strategy for treating cancers, the exact molecular mechanism by which Vorinostat mediates its radiosensitizing effect is not known. Inhibition of HDAC activity facilitates chromatin relaxation and modifies gene transcription, both processes having implications in the regulation of radiosensitivity. In addition, actively transcribing genes have been shown to be generally more sensitive to the DNA damage produced by ionizing radiation thereby producing a favorable antitumor interaction between HDAC inhibitors and radiation. One explanation for this enhanced radioresponse following treatment with HDAC inhibitors could be their effect on DNA repair processes. Generally, radiosensitivity is governed by the capacity of the cell for efficient repair of radiation-induced lesions in the DNA, mainly the repair of double-strand breaks (20–22). There have been reports in the literature that HDAC inhibitors may radiosensitize by partly suppressing the DNA repair pathways (16, 19, 23–27). Notable in this regard are the reports that Vorinostat (19, 25, 26, 28), MS-275 (19, 25, 26, 28), and valproic acid (19, 25, 26, 28) suppress the expression of DNA repair–related genes following irradiation, and that Vorinostat reduces the levels of DNA-dependent protein kinase and Rad51 in human glioma and prostate cancer cells tested (19, 25, 26, 28).

Based on these observations, we examined the effect of Vorinostat on the levels of Ku70 and Ku86 proteins by Western blot analysis. Ku70, Ku86, and DNA-dependent protein kinase catalytic subunit are key proteins that participate in nonhomologus end joining pathway, which is especially important for repairing the radiation-induced double-strand breaks that are responsible for loss of clonogenic cell survival (20–22). Down-regulation of these key DNA repair proteins has been linked with an enhanced radioresponse (29, 30). In our study, levels of Ku70 and Ku86 proteins were suppressed in A375 cells treated with Vorinostat in a dose-dependent manner. Previous investigations have also shown that reduction in Rad50 levels increased the radiation sensitivity of tumor cell lines (31, 32). Therefore, we examined the effect of Vorinostat on the levels of Rad50 protein and found a dose-dependent decrease in Rad50 levels in the A375 cells following treatment. A second approach used by us to evaluate the involvement of DNA repair was to see if treatment with Vorinostat prolonged expression of phosphorylated H2AX foci. At sites of radiation-induced DNA double-strand breaks, the histone H2AX becomes rapidly phosphorylated ({gamma}-H2AX), forming nuclear foci that can be visualized by immunofluorescence microscopy (33, 34). Although the specific role of {gamma}-H2AX in the repair of double-strand breaks is not well defined, a quantitative similarity between the induction and repair of DNA double-strand breaks and the formation and disappearance of {gamma}-H2AX foci has been found (35–38). Thus, to assess involvement of DNA repair in Vorinostat-mediated radiosensitization, we tested whether Vorinostat treatment caused a prolonged expression of {gamma}-H2AX foci indicating a decrease in the rate of repair of radiation-induced DNA double-strand breaks. Our results show that the number of radiation-induced {gamma}-H2AX foci is higher in Vorinostat-treated cells compared with controls. This is evident at times up to 1 hour following irradiation, the time frame where the majority of double-strand breaks are repaired. Thus, this persistence of foci in the Vorinostat-treated cells is interpreted as an inhibition of the double-strand break repair pathway. Recent reports indicate that persistence of repair foci correlates with enhanced radiosensitivity (16, 28, 37). We conclude that Vorinostat radiosensitizes human tumor cells by suppressing the cellular capacity for repairing radiation-induced double-strand breaks.

In summary, we have shown that Vorinostat suppresses the cellular DNA repair capacity of human tumor cells and enhances their radioresponsiveness. Inhibition of DNA repair by Vorinostat may be due to a general suppression of the levels of proteins required for this process. In addition, Vorinostat restores radiation-induced apoptosis. Our observations reported here underscore the need for continued development of strategies for sensitizing human tumor cells to cancer therapies that kill cells by inducing DNA damage and/or apoptosis.


   Footnotes
 
Grant support: University of Texas M.D. Anderson Cancer Center Institutional Clinical Translational Research Grant (A. Munshi); Melanoma Specialized Programs of Research Excellence Developmental Award (A. Munshi); grants RO1 CA69003 and PO1 CA06294 (R.E. Meyn); National Cancer Institute grant P30 CA16672 and the Kathryn O'Connor Research Professorship (R.E. Meyn).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

4 StataCorp. Stata statistical software: release 8.0. College Station (TX): Stata Corporation; 2004. Back

Received 1/13/06; revised 6/ 7/06; accepted 6/ 7/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349–52.[CrossRef][Medline]
  2. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599–606.[Free Full Text]
  3. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 2004;26:435–41.[Medline]
  4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194–202.[CrossRef][Medline]
  5. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002;11:1695–713.[CrossRef][Medline]
  6. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283–7.[CrossRef][Medline]
  7. Bohmig GA, Krieger PM, Saemann MD, et al. Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transpl Immunol 1999;7:221–7.[CrossRef][Medline]
  8. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003–7.[Abstract/Free Full Text]
  9. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165–70.[Abstract/Free Full Text]
  10. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492–7.[Abstract/Free Full Text]
  11. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996;93:5705–8.[Abstract/Free Full Text]
  12. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697–702.[Abstract/Free Full Text]
  13. Sellins KS, Cohen JJ. Gene induction by {gamma}-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987;139:3199–206.[Abstract]
  14. Butler LM, Liapis V, Bouralexis S, et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. J Invest Dermatol 2005;119:944–54.
  15. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045–52.[Medline]
  16. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11:4912–22.[Abstract/Free Full Text]
  17. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210–6.[Abstract/Free Full Text]
  18. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923–31.[Abstract/Free Full Text]
  19. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223–9.[CrossRef][Medline]
  20. Haber JE. Partners and pathwaysrepairing a double-strand break. Trends Genet 2000;16:259–64.[CrossRef][Medline]
  21. Jeggo PA. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 1998;Suppl 150:80–91.
  22. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247–54.[CrossRef][Medline]
  23. Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004;10:6066–71.[Abstract/Free Full Text]
  24. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;59:1174–80.[CrossRef][Medline]
  25. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004;161:667–74.[Medline]
  26. Camphausen K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114:380–6.[CrossRef][Medline]
  27. Jung M, Velena A, Chen B, Petukhov PA, Kozikowski AP, Dritschilo A. Novel HDAC inhibitors with radiosensitizing properties. Radiat Res 2005;163:488–93.[CrossRef][Medline]
  28. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of {gamma}H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316–21.[Abstract/Free Full Text]
  29. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 2005;65:4368–75.[Abstract/Free Full Text]
  30. Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 2005;92:1089–97.[CrossRef][Medline]
  31. Zhong H, Bryson A, Eckersdorff M, Ferguson DO. Rad50 depletion impacts upon ATR-dependent DNA damage responses. Hum Mol Genet 2005;14:2685–93.[Abstract/Free Full Text]
  32. Kim YC, Koh JT, Shin BA, et al. An antisense construct of full-length human RAD50 cDNA confers sensitivity to ionizing radiation and alkylating agents on human cell lines. Radiat Res 2002;157:19–25.[CrossRef][Medline]
  33. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858–68.[Abstract/Free Full Text]
  34. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125) IdU-induced DNA double-strand breaks with {gamma}-H2AX antibody. Radiat Res 2002;158:486–92.[CrossRef][Medline]
  35. Nazarov IB, Smirnova AN, Krutilina RI, et al. Dephosphorylation of histone {gamma}-H2AX during repair of DNA double-strand breaks in mammalian cells and its inhibition by calyculin A. Radiat Res 2003;160:309–17.[Medline]
  36. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004;58:331–5.[CrossRef][Medline]
  37. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004;279:2273–80.[Abstract/Free Full Text]
  38. MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol 2003;79:351–8.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J. M. Ford, and J. J. Buggy
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
PNAS, December 4, 2007; 104(49): 19482 - 19487.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Banuelos, J. P. Banath, S. H. MacPhail, J. Zhao, T. Reitsema, and P. L. Olive
Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781
Clin. Cancer Res., November 15, 2007; 13(22): 6816 - 6826.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Camphausen and P. J. Tofilon
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
J. Clin. Oncol., September 10, 2007; 25(26): 4051 - 4056.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munshi, A.
Right arrow Articles by Meyn, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munshi, A.
Right arrow Articles by Meyn, R. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online